Shares of St. Jude Medical (STJ +3%) claw back a bit of their 12% pummeling taken on Wednesday...
Friday, November 23, 2012, 11:50 AM ETShares of St. Jude Medical (STJ +3%) claw back a bit of their 12% pummeling taken on Wednesday following the FDA's release of a report citing serious flaws in STJ's oversight of Durata. BofA Merrill Lynch notes that the report found no new safety issues and the probability of a recall stands well below 50%, which is already priced into the stock. It reiterates a Buy with a potential downside to $24 and an upside peaking around $40.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles